ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that Harvey J. Berger, M.D., chairman and chief executive officer, and Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer, will provide an overview of the Company’s business at two upcoming investor conferences:
Both presentations will be webcast live and can be accessed by visiting the investor relations section of the Company's website at http://www.ariad.com/investor. A replay of the presentations will also be available and archived on the site for three weeks.
ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIAD’s approach to structure-based drug design has led to three internally discovered, molecularly targeted product candidates for drug-resistant or difficult-to-treat cancers, including certain forms of chronic myeloid leukemia, soft tissue and bone sarcomas and non-small cell lung cancer. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).